Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials-Reference-Cited by-同舟云学术

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials

Published:2004-07 Issue:1 Volume:148 Page:52-61
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference35 articles.

1. Alternative projections of mortality and disability by cause 1990-2020;Murray;Lancet,1997

2. Serum cholesterol, blood pressure and mortality;Martin;Lancet,1986

3. Two decades of progress in preventing vascular disease;Yusuf;Lancet,2002

4. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection;Lonn;Circulation,1994

5. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction;Flather;Lancet,2000

Cited by 354 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiorenal effects of dual blockade with Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers in people with CKD: analysis of routinely collected data with emulation of a reference trial (ONTARGET);2024-05-28

2. Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease;Cochrane Database of Systematic Reviews;2024-04-29

3. Clinical trial design for assessing hypertension medications: are critical circadian chronopharmacological principles being taking into account?;Expert Review of Clinical Pharmacology;2024-01-12

4. Triglyceride-glucose index, low-density lipoprotein levels, and cardiovascular outcomes in chronic stable cardiovascular disease: results from the ONTARGET and TRANSCEND trials;European Journal of Preventive Cardiology;2023-10-27

5. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease;Cochrane Database of Systematic Reviews;2023-07-19